The Daily Reality of Neuroradiology. High stakes. Heavy workload.
Brain metastases cannot wait.
Are you confident you found all lesions?
Is it easy to assess lesion volume and evolution?
Is your report complete?
Robovision BrainMets AI supports detecting, quantifying and tracking brain metastases. It produces clear and comprehensive reporting — while keeping existing workflows unchanged.
REQUEST EARLY ACCESS
Expert-level detection
Accurate measurement and tracking
Rapidly create comprehensive reports
Are you confident you found all lesions?
Is it easy to assess lesion volume and evolution?
Is your report complete?
Integrated, intuitive, and designed for neuroradiology workflows
01
Crafted by leading medical experts
Developed over many years in collaboration with the Netherlands Cancer Institute (NKI) with carefully curated datasets from across the globe, the BrainMets AI offers expert-level performance.
02
Detection
High-performance AI model trained to detect even the smallest metastases. Identifies potential brain metastases right down to the limit of the MRI resolution.
03
Segmentation and Quantification
Precisely measure lesion size — both diameter and 3D volume — for accurate and reproducible assessments with precise segmentations.
04
Longitudinal Tracking
Instantly compare the current study with up to four prior examinations to deliver detailed follow-up insights — both at the patient level and at the brain metastasis level.
05
Comprehensive Reporting
Generate easy-to-read reports. All in industry standard DICOM format for full compatibility with existing workflows.
With BrainMets AI
Without BrainMets AI
Detection accuracy
World-class expertise at your fingertips. Expert level sensitivity, right down to the limit of the MRI resolution.
Risk of missed lesions, especially very small or faint ones.
Consistency
Advanced software brings 24/7 consistency.
Humans are subject to variability.
Quantification
Voxel-perfect segmentations give accurate volumetric measurements.
Manual diameter measurements are time consuming and error-prone.
Follow-up assessment
BrainMets AI automatically looks up the priors and provides a full overview, at both patient and lesion level.
Manual side-by-side comparisons are tedious, error-prone and time consuming.
Report output
Patient and lesion findings are clearly and accurately displayed in an intuitive, clinician-friendly format — complete with snapshots and graphs that support faster, more confident decision-making.
Report quality varies by radiologist, and dictated formats lack evolution graphs or segmentations, making communication with clinicians—especially during tumor boards—less efficient.
Time
BrainMets AI works in the background as soon as the MRI generates its T1 sequence. By the time the radiologist opens the study, the report is conveniently attached.
Creating comprehensive reports requires significant time from busy radiologists to identify lesions, take precise measurements, and review prior studies to assess evolution over time.
Plus these additional features
Simplified Workflow Integration
Workflow integrates directly within PACS while reporting quality improves
Standardized & Future-Ready
The DICOM-compliant reporting is designed for evolving radiology needs
Expert Support for Radiologists
High-sensitivity detection, right down to the limit of the MRI resolution, means that even barely-visible lesions can be identified early to assist accurate diagnoses.
Time-Saving Automation
Automated detection, quantification, and reporting has the potential to reduce the time required by each study, allowing radiologists to get more done.
Enhanced Collaboration
Robovision presents all insights in various formats to help the radiologists rapidly create accurate and complete reports. Detailed visual overviews are useful to facilitate interdisciplinary communication and meetings.
Developed in collaboration with leading medical institutions such as the Netherlands Cancer Institute.
Currently under evaluation in clinical settings to assess impact on neuroradiology workflows.
Built under strict quality control and documentation methodologies as required by regulatory instances.
Robovision Brain Metastasis AI is a product of Robovision’s healthcare division.
Robovision applies deep learning technology across multiple segments, including MRI and CT imaging, to help specialists work faster and gain deeper insights from medical images.
Our mission is to make advanced medical insights more accessible.
Robovision Healthcare is dedicated to excellence in medical imaging and operates in a controlled quality environment as required by regulatory instances across the world.
Peer-Reviewed & Out Now
A landmark study in the prestigious Radiology Journal validates BrainMets AI's expert-level performance in brain metastasis detection, with results from real-world clinical testing. The study demonstrates unprecedented accuracy in detecting brain metastases across all sizes, setting a new standard for AI in radiology.
Get more info
LESION LEVEL
.svg)
01
Best-in-Class Perfect Patient-Level Detection
(100% sensitivity)
In this simulated real-world testing with 311 patients, BrainMets AI achieved 100% patient-level sensitivity, meaning no positive cases were missed. This zero false-negative rate ensures that the chances of not detecting brain metastases on a patient will be extremely low, no patient with brain metastases goes undetected, providing critical peace of mind for clinicians and patients alike.
PATIENT LEVEL
02
Exceptional Detection of Tiny Lesions (93.3% sensitivity)
While BrainMets AI achieves up to 100% sensitivity for larger lesions, BrainMets AI demonstrates remarkable sensitivity of 93.3% for tiny lesions under 3mm in size. This ability to detect even the smallest brain metastases enables earlier intervention, potentially months or years before these lesions would become symptomatic or visible to the naked eye.
03
Minimal False Positives (only 2%)
Despite its exceptional sensitivity, BrainMets AI maintains a remarkably low false positive rate of just 2% (only 6 cases out of 311 in the external Test dataset). This means radiologists can trust the AI's findings with minimal need for review of false positives, streamlining workflow while maintaining diagnostic confidence.
Be among the first to explore BrainMets' capabilities and support your radiology workflow with AI-assisted insights
BrainMets is an investigational AI tool currently undergoing clinical evaluation. It has not yet been approved for clinical use by the FDA or other regulatory agencies.
.webp)
Follow us
